公司表示，冻结金额相对较小，不会对日常生产经营造成重大影响。然而，此次诉讼可追溯至14年前的技术合作，所涉产品仍为欧林生物的核心产品。 值得注意的是，在2021年欧林生物成功IPO时的招股书中，并未提及王建华提供技术资料并要求提成的相关内容。经济观察网查阅招股书申报稿和注册稿 后，也未发现相关记载。 欧林生物在公告中表示，公司自成立以来，通过自主研发改良传统疫苗，并与国内外高校及科研院所合作开发创新疫苗。截至2024年末，公司有三款疫苗产 品在售，其中两款与王建华提供的技术资料有关。根据2024年年报，欧林生物b型流感嗜血杆菌结合疫苗（Hib结合疫苗）营收为2350万元，毛利率达 80.9%；A群C群脑膜炎球菌多糖结合疫苗营收为2642万元，毛利率为76.9%。2024年全年，公司实现营业收入58,885.85万元，同比增长18.69%；归属于上市 公司股东的净利润为2,075.76万元，同比增长18.24%。 经观健康 在此次诉讼相关公告中，欧林生物强调，涉及的产品均为合法上市销售的产品，其研发、生产及销售均符合国家相关法律法规，不存在权利瑕疵。 针对王建华的诉讼请求，欧林生物在公告中表示，经过对涉案合同的 ...

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. (Olin Bio, 688319.SH) is facing a lawsuit regarding two core vaccine products, leading to the freezing of some bank accounts by the court [1][2]. Group 1: Lawsuit Details - The plaintiff, Wang Jianhua, is requesting Olin Bio to pay a total of 16 million yuan for commissions related to two vaccine products and an additional 3.2 million yuan in penalties [1]. - Olin Bio has stated that it believes the lawsuit lacks sufficient factual and legal basis and will actively defend itself [2]. - The lawsuit traces back to a technical cooperation agreement signed in 2011, but Olin Bio's IPO prospectus did not mention Wang Jianhua's involvement or the claim for commissions [2][3]. Group 2: Financial Impact - Olin Bio's bank accounts have been partially frozen, with one account holding 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance [2]. - The lawsuit's claimed amount exceeds Olin Bio's net profit for the first half of 2025 [5]. - In 2024, Olin Bio reported revenues of 58.89 million yuan, a year-on-year increase of 18.69%, and a net profit of 2.08 million yuan, also up by 18.24% [4].

证券代码：688319 证券简称：欧林生物 公告编号：2026-001 成都欧林生物科技股份有限公司关于签署 A 群 C 群脑膜炎球 菌多糖结合疫苗市场推广服务协议之补充协议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 成都欧林生物科技股份有限公司（以下简称"公司"）已于 2023 年 12 月 与科园信海（北京）医疗用品贸易有限公司（以下简称"科园贸易"）在全国范 围内进行公司 A 群 C 群脑膜炎球菌多糖结合疫苗（以下简称"AC 结合疫苗"） 的市场推广服务达成一致并签署协议。 为持续深化稳定、长期的合作关系，基于双方对市场环境的共同研判，经 友好协商，公司与科园贸易签署了《A 群 C 群脑膜炎球菌多糖结合疫苗市场推广 服务协议之补充协议》，对原协议有效期进行优化调整，其他核心条款保持不变。 对上市公司当期业绩的影响：该协议的签署预计不会对公司当期经营业绩 产生重大影响。 合同履行中的重大风险及重大不确定性：本协议约定的推广任务量并不等 于实际销量，不构成业绩承诺，具体的销售情况存在不确定性。 ...

Group 1 - The core viewpoint of the article is that Olin Bio (688319.SH) has signed a supplementary agreement with Keyuan Trading to optimize the effective period of their original market promotion service agreement for the A group and C group meningococcal polysaccharide conjugate vaccine [1] - The supplementary agreement was reached based on a mutual assessment of the market environment and aims to deepen a stable and long-term cooperative relationship between the two parties [1] - Other core terms of the original agreement remain unchanged despite the optimization of the effective period [1]

Group 1 - The core viewpoint of the article is that Olin Bio (688319.SH) has signed a supplementary agreement with Keyuan Trading to optimize the effective period of their original market promotion service agreement for the A group and C group meningococcal polysaccharide conjugate vaccine [1] - The supplementary agreement was reached based on mutual assessment of the market environment and aims to deepen a stable and long-term cooperative relationship between the two parties [1] - Other core terms of the original agreement remain unchanged despite the optimization of the effective period [1]

Core Viewpoint - The company has signed a supplementary agreement with Keyuan Trading to optimize the promotion period for the AC combined vaccine from 2024 to 2029, with a total promotion task of 4 million doses [1] Group 1 - The initial agreement was signed in December 2023, with a promotion task of 4 million doses from 2024 to 2026 [1] - The new agreement extends the collaboration period to January 1, 2024, through December 31, 2029, while keeping other core terms unchanged [1] - The expected vaccine sales for 2024 are projected at 252,000 doses, but there are uncertainties regarding the completion of the promotion task and the fulfillment of the agreement [1]

Core Viewpoint - Oulin Bio has received a lawsuit notification from the Chengdu Intermediate People's Court regarding a claim made by the plaintiff Wang Jianhua for commission payments related to specific vaccine products [1] Group 1: Lawsuit Details - The plaintiff, Wang Jianhua, claims to have provided technical materials for two vaccine products and is seeking a total of 16 million yuan in commission payments [1] - Additionally, Wang Jianhua is requesting a penalty of 3.2 million yuan, calculated at 20% of the claimed commission amount [1] - Oulin Bio has acknowledged the lawsuit and asserts that the claims lack sufficient factual and legal basis, indicating a strong stance against the allegations [1] Group 2: Current Status - As of the date of the announcement, the lawsuit has not yet gone to trial, and the claimed amounts represent the plaintiff's assertions rather than any court ruling [1]

Core Viewpoint - Oulin Biotech is facing a lawsuit involving a contract dispute with an individual, Wang Jianhua, over a total amount of 19.2 million yuan, which includes penalties and is currently under court proceedings [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Wang Jianhua is entitled to a commission of 16 million yuan for providing technical materials related to specific vaccines, along with a penalty of 3.2 million yuan calculated at 20% of the commission [3]. - Oulin Biotech has acknowledged receipt of the legal documents and asserts that the claims lack sufficient factual and legal basis, thus rejecting the plaintiff's demands [3][4]. Group 2: Financial Impact - The court has frozen 1 non-basic bank account of the company, with the frozen amount of 19.2 million yuan representing 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [4]. - The company reported a revenue of 589 million yuan in 2024, marking an 18.69% year-on-year increase, and a net profit of 20.76 million yuan, up 18.24% from the previous year [5]. Group 3: Company Background - Oulin Biotech specializes in the research, production, and sales of human vaccines and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in June 2021 [5]. - The company has only three commercialized products and has experienced significant profit declines in 2022 and 2023, with net profits dropping by 75.38% and 33.94%, respectively [5].

Core Viewpoint - Oulin Bio (688319) is facing a lawsuit regarding a contract dispute with individual Wang Jianhua, involving a total claim amount of 19.2 million yuan, which includes penalties but excludes litigation costs [1][2]. Group 1: Lawsuit Details - The lawsuit stems from a contract signed in 2011, where the plaintiff claims to have fulfilled obligations by providing two vaccine technologies and is thus entitled to a commission [1]. - Wang Jianhua's claims include a request for 16 million yuan in product commissions, 3.2 million yuan in penalties, and coverage of all litigation costs [1]. Group 2: Company Response - Oulin Bio has acknowledged receipt of legal documents and asserts that the plaintiff's claims lack sufficient factual and legal basis, thus rejecting the claims [2]. - The company emphasizes that the products involved in the lawsuit are legally marketed and compliant with relevant laws and regulations, indicating no significant adverse impact on its operations [2]. Group 3: Financial Impact - The court has frozen one non-basic bank account with a total of 19.2 million yuan, which represents 2.06% of the company's latest audited net assets and 8.57% of its cash balance, indicating a relatively minor impact on daily operations [2]. - The lawsuit's financial implications remain uncertain until the court reaches a decision, and the company will handle financial reporting in accordance with accounting standards [3]. Group 4: Commitment to Compliance - Oulin Bio, as an innovative technology company, emphasizes its commitment to intellectual property compliance and the regulation of technology cooperation, stating that all R&D activities adhere to legal requirements [3].

证券代码：688319 证券简称：欧林生物 公告编号：2025-068 成都欧林生物科技股份有限公司 关于涉及诉讼的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本次诉讼的基本情况 近日，成都欧林生物科技股份有限公司（以下简称"公司"）收到了四川省 成都市中级人民法院送达的《应诉通知书》及相关材料。 截至本公告披露日，该案件已立案，尚未开庭审理。 （四）诉讼请求 1.请求法院依法判令被告向原告支付"A、C 群脑膜炎球菌多糖疫苗及用破伤 风类毒素作为载体的结合疫苗"以及"用破伤风类毒素作为载体的 Hib 结合疫苗" 的两项产品提成共计 1600 万元； 2.请求法院依法判令被告向原告支付违约金 320 万元(以 1600 万元为基数， 按合同约定的 20%计算)； 3.请求法院依法判令被告承担本案全部诉讼费用、保全费用及其他实现债权 所产生的合理费用。 三、公司的说明 针对原告提起的诉讼，公司已收悉相关法律文件并予以高度重视。经对案涉 合同的全面审阅与分析，公司认为，原告诉讼请求缺乏充分的事实与法 ...